Skip to main content

Table 2 Patients characteristics

From: Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

  Total (N = 407)
Sex, n (%)  
   Female 110 (27.0)
   Male 297 (73.0)
Mean age (SD), years 61.9 (12.0)
ECOG PS, n (%) 370
   0 110 (29.7)
   1 206 (55.7)
   2 44 (11.9)
   3 10 (2.7)
Histology, n (%) 399
   Clear cell 357 (89.5)
   Papillary 21 (5.3)
   Cromophobe 9 (2.3)
   Sarcomatoid 4 (1.0)
   Mixed 3 (0.8)
   Collecting Duct 1 (0.3)
   Others 4 (1.0)
*Targeted treatment, n (%)  
   Sunitinib 251 (61.7)
   Sorafenib 62 (15.2)
   Pazopanib 56 (13.8)
   Everolimus 70 (17.2)
   Temsirolimus 37 (9.1)
   Bevacizumab 5 (1.2)
  1. * Some patients received more than one treatment
\